OpenAI Promotes Broader Use of AI in Life Sciences Through Increased Lobbying Expenditure and Policy Team
OpenAI is promoting the broader application of AI in the life sciences by increasing lobbying expenditures and its policy team. In 2025, OpenAI's federal lobbying expenditure reached a new high, actively influencing AI safety and regulatory frameworks in places like California, while collaborating with government agencies and large pharmaceutical companies such as Novo Nordisk to apply AI models in drug discovery, disease research, and clinical workflows. At the beginning of 2026, the OpenAI Foundation announced a commitment of at least $1 billion to the life sciences and healthcare sector, aimed at accelerating new drug development, improving diagnostics, and expanding access to public health data, while addressing the potential risks of AI on employment and biosafety.
OpenAI is aligning with major AI companies in Washington, emphasizing three priority issues: AI infrastructure, national security, and data rights, with support for life sciences positioned as a core pillar of the "AI societal dividend." As OpenAI's collaborations and lobbying in the life sciences unfold, its goal is to transition AI from an "experimental tool" to a "formal R&D layer" recognized by regulators, pharmaceutical companies, and research institutions.
Source: Public Information
ABAB AI Insight
OpenAI在生命科学领域的游说，反映的是AI从“实验性技术”到“基础设施”的地位升级。在药物研发、临床试验和基因组学等场景，AI模型不再只是“辅助分析”，而是被嵌入到研发流程的正式环节中。这要求监管机构重新评估AI在安全性和合规性方面的权重，也需要OpenAI在政策框架中占据“合规‑技术‑伦理”三位一体的有利位置。
从结构上看，这场游说的重心之一是“数据与安全”：AI在生命科学中的应用高度依赖高质量、标准化的数据，而监管机构对数据隐私和生物安全的关切，正是OpenAI等公司需要在政策层面解决的核心问题。通过提前与监管机构建立合作与沟通，OpenAI可以将AI在生命科学中的角色“合规化”，从而降低政策风险，同时为未来的模型应用铺设道路。
长期趋势上，OpenAI在生命科学领域的布局，将使AI在医疗研发中成为“第二层基础设施”——在药物研发、公共健康和生物安全领域，AI将像计算平台一样，为研究机构和制药公司赋能。这种政策─技术─资本的协同，不仅会加速新药上市速度和降低研发成本，也将重新定义AI在生命科学领域的“监管边界”和“伦理框架”。一旦OpenAI在生命科学领域建立了“合规‑模型‑政策”领先地位，它在其他领域的AI应用也将更易被监管和市场接受。